Thema: US87164F1057
SNDX, US87164F1057
stock-5275746_1920.jpg - Foto: THN
Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts
Syndax Pharmaceuticals stock has 19 abstracts accepted for ASH 2026, including seven oral revumenib presentations. An investor event follows in December.
ad-hoc-news.de, heute 00:20 Uhr
SNDX, US87164F1057
Syndax halts IPF development: Wainwright keeps USD 38 target ...
Second-quarter revenue reached USD 72.79 million. Syndax Pharmaceuticals stock costs EUR 11.71 on October 20, 2026 before November 2 results.
ad-hoc-news.de, 20.10.26 13:43 Uhr
SNDX, US87164F1057
Syndax gets TIME recognition as Wainwright keeps USD 38 ...
Syndax's Revuforj entered TIME's 2026 list on October 15, 2026. A USD 38.00 target stayed in place for Syndax Pharmaceuticals stock.
ad-hoc-news.de, 18.10.26 13:26 Uhr
SNDX, US87164F1057
HC Wainwright keeps USD 38.00 target for Syndax Pharmaceuticals ...
Syndax kept its USD 38.00 target on October 13, 2026. Syndax Pharmaceuticals stock trades at EUR 12.14 on October 15, 2026.
ad-hoc-news.de, 15.10.26 13:14 Uhr
Syndax, Pharmaceuticals
Syndax Pharmaceuticals: Key Investor Presentation to Outline ...
Syndax US87164F1057
boerse-global.de, 05.02.26 22:34 Uhr
Syndax, Pharmaceuticals
Syndax Pharmaceuticals Nears Critical Regulatory Milestone ...
